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The chemokine receptor CXCR4 functions as one of the HIV-1 coreceptors and can be considered as an attractive target for the development of
novel anti-HIV drugs. Here, we investigated the effect of its two known N-glycosylation sites g1 (NYT) and g2 (NVS) on the antiviral potential of
several classes of entry inhibitors. The lack of g1 clearly affected the binding of the amino-terminal directed 2B11 mAb, but not the 12G5 mAb.
No dramatic effects on CXCL-12 binding and CXCL-12-induced intracellular calcium responses were observed. Importantly, the anti-HIV-1
activity and antagonistic activity of the prototype compound of CXCR4 inhibitors, AMD3100, were not affected by the presence or absence of the
CXCR4 N-glycans.
Since CXCR4 N-glycans play a less important role in viral entry compared to the N-glycans on the HIVenvelope, cells expressing CXCR4 N-
glycosylation mutants might be no relevant alternative to allow HIV-1 escape from antivirals.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV-1; CXCR4; N-glycosylation; AMD3100; LectinsIntroduction
Binding of the gp120 envelope protein of HIV-1 to the
cellular CD4-receptor induces conformation changes and
results in the exposure of the coreceptor-binding sites. Then
gp120 further interacts with one of the two chemokine
receptors, CCR5 or CXCR4, to achieve the final conformational
changes that are required for efficient membrane fusion. HIV-1
gp41 unfolds, inserts in the cell membrane and fusion can occur
(Alkhatib et al., 1996; Berson et al., 1996; Choe et al., 1996;
Deng et al., 1996; Doranz et al., 1996; Dragic et al., 1996; Feng
et al., 1996).
The chemokine receptor CXCR4 belongs to the seven-
transmembrane-domain G-protein-coupled receptor family
(Deng et al., 1996; Feng et al., 1996). Its natural ligand is the
chemokine stromal cell-derived factor (SDF-1/CXCL-12)⁎ Corresponding author. Fax: +32 16 337340.
E-mail address: Dominique.schols@rega.kuleuven.be (D. Schols).
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doi:10.1016/j.virol.2007.01.031(Bleul et al., 1996; Oberlin et al., 1996). CXCR4 is the major
coreceptor for X4 HIV-1 viruses that appear at later stages of
HIV-1 infection and their appearance is associated with
accelerated CD4+ T-cell decline and clinical progression
towards AIDS (Connor et al., 1997; Malkevich et al., 2001;
Schramm et al., 2000). The V3 loop of gp120 interacts with the
N-terminal region and extracellular domains of CXCR4
(Cocchi et al., 1996). Changes in these regions of the
CXCR4 receptor and in the V3 loop of HIV-1 can influence
virus entry. It is known that the overall positive charge of the
V3 loop is correlated to the usage of CXCR4 and CCR5 (a high
positive charge promotes CXCR4 usages and a low positive
charge promotes CCR5 usages) (Zhong et al., 1995). Both
gp120 and CXCR4 are subject to N-glycosylation. The
complete gp120 is a highly glycosylated protein which contains
between 20 and 29 potential N-linked glycosylation sites and
the carbohydrate content constitutes about 50% of the mass of
gp120 (Leonard et al., 1990). Lack of some N-glycan structures
within the gp120 V3 loop of the HIV-1 NL4.3 strains resulted
in an enhanced infectivity in CXCR4-expressing cells (Pollakis
et al., 2001; Polzer et al., 2001). It is hypothesized that the
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amino acids. It was also proposed that the carbohydrates act as
a shield to protect the virions from the humoral immune
response (Wyatt et al., 1998). Thus, compounds interacting
with the carbohydrate domains on the virion envelope might
provide effective ways to inhibit viral infection. The broadly
neutralizing mAb 2G12, the mannose-specific plant lectins
derived from Galanthus nivalis (GNA) and Hippeastrum
hybrid (HHA) and the N-acetylglucosamine-binding protein
from Urtica dioica (UDA) bind to the HIV envelope protein in
a carbohydrate-dependent manner and significantly inhibit
HIV-1 replication (Balzarini et al., 2004, 2005; Balzarini, 2006;
Calarese et al., 2003; Scanlan et al., 2002).
Studies have shown that the CXCR4 coreceptor is present in
different antigenically distinct conformations in vivo and that
the heterogeneity observed is cell-type-dependent (Baribaud et
al., 2001; Baribaud and Doms, 2001). N-Glycosylation is also
cell-type-dependent, thus it is conceivable that the various
forms of CXCR4 can be the result of changes in N-glyco-
sylation. CXCR4 contains only two potential N-glycosylation
sites at amino acid positions 11–13 (g1) and 176–178 (g2) (Fig.
1). It has been shown previously that glycosylation influences
the ability of CXCR4 to serve as a coreceptor for T-tropic (X4)
and dual-tropic (R5X4) HIV-1 strains. Chabot et al. (2000)
found that removal of a site of N-linked glycosylation allows
CXCR4 to serve as a more universal coreceptor, allowing
efficient entry of several HIV-1 isolates that normally use only
CCR5. Thordsen et al. (2002) found a similar permissiveness
for an X4 virus and no exchange in coreceptor specificity that
allows infection of an R5 virus. However, removal of glycan g1Fig. 1. Amino acid sequence and membrane organization of the chemokine receptor
the N-glycosylation sites g1 (AA N11Q-T13A) and g2 (AA N176Q-S178A).significantly enhanced the permissiveness for a dual-tropic R5/
X4 virus. If g1 is masking some of the positively charged amino
acids on CXCR4, the deletion of g1 would therefore reduce the
overall negative charge of the CXCR4 coreceptor, increasing
the infectivity of dual-tropic virus.
In this study, we further investigated the role of the N-linked
glycosylation sites of CXCR4. Several experiments were
performed to test the binding of CXCL-12 and anti-CXCR4
monoclonal antibodies (mAbs) to the mutant CXCR4 receptors
and the inhibitory effect of the CXCR4 antagonist AMD3100
was also investigated (Donzella et al., 1998; Hatse et al., 2002;
Schols et al., 1997b). The infectivity of the NL4.3 virus and
several in vitro generated entry inhibitor resistant NL4.3 viruses
was also investigated.
Results and discussion
Establishment of the U87.CD4.CXCR4 glycosylation mutants
Because of its complete lack of endogenous CXCR4
expression (and many other chemokine receptors), we used the
U87.CD4 cell line as a starting point to create the CXCR4
glycosylation mutants. The pBABE-puro vectors with mutated
CXCR4 genes (i.e. CXCR4 [WT], CXCR4 [N11Q], CXCR4
[N176Q], CXCR4 [N11Q, N176Q], CXCR4 [T13A] and
CXCR4 [S178A] (Fig. 1)) were transfected into the U87.CD4
cells using FuGENE 6 Transfection Reagent and selected further
with puromycin. We evaluated the CXCR4 expression with the
anti-CXCR4 mAb clone 12G5 and the CXCR4 glycosylation
mutants stained 82%–97% positive with this mAb as measuredCXCR4 with indication of the positions of the mutated amino acids that remove
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mutant, used as a control for the transfection procedure and for
further experiments, was 89% CXCR4-positive.
Effect of CXCR4 glycans on antibody recognition
HIV-1 entry can be influenced by receptor density and
potentially by receptor conformation. It has been shown that
CXCR4 can exist in antigenically distinct conformations on
certain cell types and it is conceivable that the various formsFig. 2. Flow cytometric analysis of the CXCR4 membrane expression of the differe
staining by 12G5 mAb. The left panel represents the background fluorescence of th
presented in the upper-right corner of each dot plot.could be the result of changes in N-glycosylation. Therefore, we
evaluated the antibody binding capacities in the different
CXCR4 mutants using 2 CXCR4-specific mAbs i.e. the clone
12G5 and 2B11. The mAb 12G5 mainly targets the second
extracellular loop while the 2B11 mAb binds the amino-
terminal loop of the CXCR4 receptor.
Table 1 shows the mean fluorescence intensities (MFI) for
12G5 mAb and 2B11 mAb binding. The MFI values for 12G5
mAb binding were comparable for all the generated CXCR4
mutants, so the lack of N-glycosylation sites did not noticeablynt U87.CD4 transfected cell lines. The right panel represents CXCR4-specific
e non-specific binding of an isotype mAb. The percentage of CXCR4+ cells is
Table 1
Mean fluorescence intensities (MFI) of the binding of the chemokine CXCL-
12AF647 and two different anti-CXCR4 mAbs 12G5 and 2B11
MFI a
CXCL-12AF647
binding
12G5 mAb
binding
2B11 mAb
binding
CXCR4 WT 23.8±5.8 63.6±10.9 16.7±9.3
CXCR4 [N11Q] 21.3±6.7 64.0±17.7 5.9±1.9
CXCR4 [N176Q] 28.0±2.8 55.4±9.6 7.8±4.7
CXCR4 [N11Q, N176Q] 13.7±3.5 81.2±11.5 18.3±13.9
CXCR4 [T13A] 14.2±0.5 20.2±6.4 1.6±1.5
CXCR4 [S178A] 37.3±2.6 54.7±19.5 11.0±3.6
a Flow cytometric analysis of the binding of CXCL-12AF647, 12G5 mAb and
2B11 mAb. The values are the mean±S.D. of mean fluorescence intensities
(MFI) from 3 to 4 separate experiments.
Table 2
Inhibitory effects of the CXCR4 inhibitor AMD3100
IC50
a (ng/ml)
CXCL-12AF647
binding
12G5 mAb
binding
Ca2+
signaling
CXCR4 WT 63.4 2.5 61.4±8.6
CXCR4 [N11Q] 21.9 2.9 26.8±1.8
CXCR4 [N176Q] 30.8 6.3 100.7±86.8
CXCR4 [N11Q, N176Q] 21.8 2.7 63.5±14.4
CXCR4 [T13A] 40.2 3.8 142.9±49.6
CXCR4 [S178A] 23.2 3.4 29.1±6.0
a 50% inhibitory concentration of AMD3100 to inhibit for 50% CXCL-
12AF647 binding, 12G5 mAb binding and CXCL-12-induced calcium signaling
in the different U87.CD4.CXCR4 mutants. The values are the mean of two
experiments (for CXCL-12AF647 binding and 12G5 mAb binding) or the mean
±S.D. of three separate experiments (for Ca2+ signaling).
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2B11 binding were not comparable for all the CXCR4 mutants.
The MFI values for both the CXCR4 [N11Q] mutant and the
[T13A] mutant were lowest compared to the WT CXCR4
receptor mutant cell line. So, the lack of the g1 N-glycosylation
site clearly disturbed the binding of the 2B11 mAb to the amino-
terminal loop of CXCR4. Chabot et al. (2000) also demon-
strated that the binding of 12G5 mAb (2B11 mAb was not used
in their study) was comparable for the different N-glycosylation
CXCR4 mutants.
To find out whether the N-glycosylation sites have an
influence on the activity of the CXCR4 inhibitor AMD3100 we
investigated the effect of AMD3100 on the 12G5 mAb
binding. The IC50 values of AMD3100 are shown in Table 2
and are comparable for all the different CXCR4 mutants.
Therefore, the binding of AMD3100 to CXCR4 is not in-
fluenced by the N-glycosylation sites. AMD3100 does not
interfere with the binding of the 2B11 mAb, as described pre-
viously on untransfected CXCR4+ cells (Schols and De Clercq,
2001).
Effect of CXCR4 glycans on CXCL-12AF647 binding
The U87.CD4.CXCR4 wild-type and glycosylation mutants
were then incubated with different concentrations of the Alexa-
Fluor647-labeled CXCL-12 (CXCL-12AF647) (100 ng/ml,
20 ng/ml and 4 ng/ml) for 30 min. The fluorescence increased
gradually with increasing concentrations of CXCL-12AF647
(data not shown). We compared the mean fluorescence intensity
(MFI) measured when the different mutant cells were incubated
with CXCL-12AF647 at 100 ng/ml. These values were compar-
able (MFI ranging from 13.7 to 37.3), thus the lack of g1 or g2
on CXCR4 did not influence dramatically the binding of the
labeled CXCL-12 (Table 1).
Here, we also wanted to know whether the inhibitory effect
of the compound AMD3100 was influenced by the absence of
N-glycosylation sites. The IC50 values were comparable for all
the mutant CXCR4 receptors (Table 2), but in general the
concentration of AMD3100 needed to block CXCL-12-binding
was higher than the concentration needed to block 12G5 mAb
binding.Effect of CXCR4 glycans on chemokine-induced intracellular
calcium mobilization assays
After binding to the receptor, chemokines trigger an intra-
cellular signal transduction cascade comprising a transient cy-
tosolic calcium mobilization. To examine the binding of CXCL-
12 to the mutated CXCR4 receptors we performed intracellular
calcium mobilization assays on these mutants and compared
their responses to those of the wild-type U87.CD4.CXCR4
cells. Again we evaluated the inhibitory effect of the CXCR4
antagonist AMD3100. After loading the cells with the fluo-
rescent calcium indicator Fluo-3, the cells were incubated with
CXCL-12 and in order to investigate the effect of AMD3100 the
cells were pre-incubated for 10 min with the antagonist before
chemokine stimulation.
Fig. 3 shows the intracellular calcium flux in the different
CXCR4 mutants. In all the mutants, after stimulation with
CXCL-12 at 100 ng/ml, the calcium fluxes were comparable to
the wild-type cells (a fluorescence change from 2000 to 3000
counts) except for the CXCR4 [N11Q] mutant who had always a
higher calcium flux signal (about 5000 counts). The antagonist
AMD3100 completely blocked the CXCL-12-induced intracel-
lular calcium flux at 1 μg/ml in all mutant cell lines (Fig. 3).
Calcium signaling was inhibited in a dose-dependent manner by
AMD3100, with 50% inhibitory concentrations of 61 ng/ml,
27 ng/ml, 101 ng/ml, 63 ng/ml, 143 ng/ml and 29 ng/ml for
CXCR4 [WT], CXCR4 [N11Q], CXCR4 [N176Q], CXCR4
[N11Q, N176Q], CXCR4 [T13A] and CXCR4 [S178A]
respectively (Table 2). These values are quite comparable with
the values achieved with the CXCL-12AF647 binding assay.
Effect of CXCR4 glycans on X4 HIV-1 infection
To investigate whether the U87.CD4.CXCR4 mutant cells
supported HIV-1 replication, cells were infected with various
inputs of the laboratory HIV-1 X4 NL4.3 strain. At several days
after infection (day 3, 5 and 7), the cytopathic effect (CPE) was
microscopically compared in the different mutant cell lines.
HIV-1 NL4.3 infected all the different mutants in a very
consistent and reproducible manner. Also, when the infectivity
of three resistant HIV-1 NL4.3 viruses, NL4.3 resistant to the
Fig. 3. CXCL-12-induced intracellular calcium mobilization and inhibition by AMD3100. Fluo-3 loaded cells were incubated with AMD3100 (at 1 μg/ml) or with
assay buffer only for 10 min, then CXCL-12 (at 100 ng/ml) was added. The transient increase in intracellular calcium concentration was recorded by monitoring the
change in green fluorescence intensity of the cells as function in time by using the FLIPR. Each data point represents the average of the fluorescence measured in
quadruplicate.
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AMD3100 and NL4.3 resistant to the neutralizing 2G12 mAb
was evaluated, no differences were detected in viral replication
(as evaluated by CPE and p-24 viral Ag production) of these
viruses in the different U87.CD4.CXCR4 mutant cells. Thus,
the infectivity of NL4.3 and several entry inhibitor resistant
viruses (to CXCL-12, AMD3100 and the 2G12 mAb) was not
affected by the presence or absence of the glycosylation sites in
CXCR4. When we evaluated the R5 laboratory strains JR-FL,
ADA, Ba-L and SF-162 no CPE or any p-24 viral Ag
production could be detected. Chabot et al. (2000) described
that R5 viruses were able to infect some of the N-linked CXCR4
mutants (expressed on U373 cells) whereas Thordsen et al.
(2002) reported that R5 viruses were not able to infect these
mutants (expressed on GHOST cells).
The antiviral activity of AMD3100, the plant lectins GNA,
HHA and UDA and the 2G12 mAb was determined for HIV-1NL4.3 in the different U87.CD4.CXCR4 mutant cell lines
(Table 3). AMD3100 showed a potent and consistent antiviral
activity against HIV-1 NL4.3 with an IC50 slightly varying from
3 to 11 ng/ml. The plant lectins were less active than AMD3100,
but no significant differences in anti-HIV activity were
observed. The 2G12 mAb was not active at a concentration of
2 μg/ml in these mutant cells. Thus, no difference was observed
in the antiviral activity of AMD3100 and the plant lectins in the
different CXCR4 mutants and we can conclude that the N-
glycosylation sites have no effect at all on the antiviral activity
of these classes of entry inhibitors.
Conclusion
CXCR4 is one of the two major coreceptors for HIV.
Therefore it is important to study the characteristics of the
CXCR4 receptor in the multifaceted mechanism of HIV
Table 3
Anti-HIV-1 activity of AMD3100, the plant lectins HHA, GNA and UDA and
the anti-carbohydrate mAb 2G12
IC50
a (μg/ml)
AMD3100 HHA GNA UDA 2G12
mAb
CXCR4 WT 0.005±0.010 0.56±0.5 1.7±0.9 1.9±0.5 >2
CXCR4 [N11Q] 0.007±0.005 0.36±0.9 1.1±0.5 1.5±0.7 >2
CXCR4 [N176Q] 0.003±0.005 0.29±0.5 0.33±0.2 1.1±0.6 >2
CXCR4 [N11Q,
N176Q]
0.009±0.007 0.35±0.2 0.95±0.5 1.5±0.5 >2
CXCR4 [T13A] 0.011±0.008 0.96±0.5 0.75±0.9 1.4±0.5 >2
CXCR4 [S178A] 0.004±0.010 0.25±0.9 1.7±0.5 1.4±0.4 >2
a 50% inhibitory concentration to inhibit HIV-1 NL4.3-induced CPE by 50%
in the different U87.CD4.CXCR4 mutants. The values are the mean±S.D. from
3 to 5 separate experiments.
285D. Huskens et al. / Virology 363 (2007) 280–287infection. A better understanding of the interactions between the
CXCR4 receptor and the gp120 of HIV can facilitate the
development of therapeutic approaches to inhibit virus entry. In
summary, we found that the lack of the g1 N-glycosylation site on
CXCR4 disturbed the binding of the amino-terminal binding
2B11 mAb and somewhat enhanced the calcium flux in response
to CXCL-12. The N-glycosylation g1 and g2 sites had no
influence on its coreceptor function for HIV-1 NL4.3 wild-type
and several entry inhibitor-resistant viruses generated in vitro
(such as CXCL-12, AMD3100 and the 2G12mAb). Furthermore,
our data point to the potent and consistent antiviral and
antagonistic activity of AMD3100 being independent for the
presence of g1 or g2 on CXCR4 and also of the broad antiviral
activity of the lectins GNA,HHA andUDA. Because the different
forms of the CXCR4 receptor present in vivo are possibly the
result of changes in N-glycosylation it is important to show that
these different forms have no influence on the infectivity of X4
viruses and various entry inhibitor-resistant X4 viruses. Even
more important is that the antivirals preserve their antiviral
activity against X4 viruses, so the N-glycosylation mutations in
CXCR4 are no alternative to allow an escape route for the virus.
Materials and methods
Cell cultures and viruses
Human astroglioma U87 cells expressing human CD4 (U87.
CD4) were a kind gift of Dr. Dan R. Littman (Skirball Institute
of Biomolecular Medicine, New York, NY, USA). These cells
were transfected with the CXCR4 mutants (as described below)
and cultured in Dulbecco's modified Eagle's medium (Invitro-
gen, Paisley, UK) containing 10% fetal bovine serum (FBS)
(BioWhittaker Europe, Verviers, Belgium), 0.01 M HEPES buf-
fer (Invitrogen), 0.2 μg/ml geneticin (G-418 sulfate) (Invitrogen)
and 1 μg/ml puromycin (Sigma-Aldrich, St. Louis, MO, USA).
The cell cultures were maintained at 37 °C in a humidified
CO2-controlled atmosphere and subcultivations were done
every 2 to 3 days by digestion of the monolayers with trypsin/
EDTA (Invitrogen).
HIV-1 NL4.3 was obtained through the AIDS Research and
Reference Reagent Program (Division of AIDS, NIAID, NIH).HIV-1 NL4.3 resistant strains to the bicyclam AMD3100 and to
the chemokine CXCL-12 have previously been established and
were characterized in our laboratory (de Vreese et al., 1996;
Schols et al., 1997a, 1998). HIV-1 NL4.3 resistant to the mAb
2G12 has also been established in our laboratory (Huskens et
al., in press).
Compounds and chemokines
The bicyclam AMD3100 was synthesized as described
previously (Bridger et al., 1995). The mannose-specific plant
lectins from G. nivalis (GNA) and Hippeastrum hybrid (HHA)
and the N-acetylglucosamine-specific lectin from U. dioica
(UDA) were derived and purified from the bulbs/roots of these
plants, as described before (Balzarini, 2006; Kaku et al., 1990;
Van Damme et al., 1987, 1988, 1991). The human chemokine
CXCL-12 (SDF-1) was purchased from PeproTech (London,
United Kingdom) and CXCL-12AF647 (a human CXCL-12
carrying an Alexa-Fluor647 moiety at its second to last amino
acid position) was obtained from CCS Albachem (United
Kingdom) (Hatse et al., 2004).
Construction of CXCR4 glycosylation mutants
The pBABE-puro vectors (containing a puromycin resis-
tance gene) with mutated CXCR4 genes in their unique EcoRI
restriction sites were described in detail (Polzer et al., 2002;
Thordsen et al., 2002). These pBABE-puro vectors were stably
transfected into the U87.CD4 cells using FuGENE 6 Transfec-
tion Reagent (Roche Molecular Biochemicals, Mannheim,
Germany) according to the manufacturer's instructions. Pur-
omycin selection (1 μg/ml) was started after 24 h and
puromycin-resistant cell cultures were established after approxi-
mately 3 weeks.
Flow cytometric analyses
The antibodies used in this study were: PE-conjugated
mouse anti-human CXCR4 mAb clone 12G5 (R&D Systems
Europe, Oxen, United Kingdom) and PE-conjugated rat anti-
CXCR4 mAb clone 2B11 (BD Pharmingen, San Diego, CA,
USA). As a control for a specific background staining, the
cells were stained with Simultest Control, γ1/γ2α FITC/PE
(Becton Dickinson). After trypsin digestion the CXCR4-
transfected U87.CD4 cells were incubated for at least 1 h at
room temperature to allow re-expression of receptor proteins
on the cell surface. Then, the cells were washed in PBS with
2% FBS and for each sample 0.3×106 cells were resuspended
in 100 μl PBS/FBS 2%. Thereafter, antibodies were added
and samples were incubated for 45 min at room temperature.
After incubation the cells were washed and resuspended in
300 μl PBS containing 1% paraformaldehyde and analyzed
on a FACSCalibur flow cytometer (Becton Dickinson, San
Jose, CA).
To evaluate the effect of AMD3100 on antibody binding, the
cells were pre-incubated in PBS/FBS 2% for 15 min at room
temperature with the chemokine receptor antagonist AMD3100
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with the antibodies. For the calculation of the mAb binding, the
mean fluorescence intensity (MFI) of each sample was
expressed as percentage of the MFI of control cells and the
IC50 values of the compound were then calculated.
The CXCL-12AF647 binding assay has been described by
Hatse et al. (2004). Briefly, CXCR4-transfected U87.CD4 cells
were washed once in assay buffer (Hanks' balanced salt solution
with 20 mM HEPES buffer and 0.2% bovine serum albumin,
pH 7.4) and incubated with CXCL-12AF647 diluted in assay
buffer for 30 min at room temperature. Then the cells were
washed, fixed in 1% paraformaldehyde in PBS and analyzed on
the FL4 channel (661/16 nm) of a FACSCalibur flow cytometer
equipped with a 635-nm red diode laser (Becton Dickinson). To
evaluate the inhibitory effect of AMD3100 on the binding of
CXCL-12AF647 the cells were incubated with AMD3100 diluted
in assay buffer for 15 min at room temperature, washed and then
incubated with CXCL-12AF647 (100 ng/ml) for 30 min at room
temperature.
Calcium signaling assays
The U87.CD4.CXCR4 mutant cells were digested by trypsin
and seeded in gelatin-coated (0.2%) black-wall 96-well
microplates (Costar, Cambridge, MA) at 2×104 cells per well
the day before the experiment. The next day, the cells were
loaded with the fluorescent calcium indicator Fluo-3 acetox-
ymethyl (Molecular Probes, Leiden, The Netherlands) at 4 μM
for 45 min at 37 °C. Then cells were washed with assay buffer
(see above) and incubated with 150 μl AMD3100 at different
concentrations, diluted in assay buffer, for 10 min at 37 °C. The
intracellular calcium signaling in response to 100 ng/ml CXCL-
12 was measured in all 96 wells simultaneously as a function in
time, using the Fluorometric Imaging Plate Reader (FLIPR)
(Molecular Devices, Sunnyvale, CA) as described previously
(Princen et al., 2003).
HIV infection assays
The U87.CD4.CXCR4 transfectants were seeded in 24-well
plates (2×104 cells per well) and different concentrations of
HIV-1 virus (5000–1.6 pg/ml p24 antigen (Ag)) were added.
The cytopathic effect of virus replication in the cell cultures
(syncytium formation) was evaluated microscopically every
day up to 7 days after infection. To examine the antiviral activity
of AMD3100, plant lectins and 2G12 mAb the cells were
seeded out in 24-well plates already containing these agents at
various concentrations and then virus was added. After 7 days
the cytopathic effect (CPE) was evaluated microscopically.
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